Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myfortic with reduced versus standard corticosteroids for lupus nephritis
2006-002107-13Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mycophenolate sodium and corticosteroids in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (2 arms), sponsored by Novartis. Primary endpoint: Complete remission at 24 weeks. Started Oct 2006; status: completed.
02
Drugs
mycophenolate sodiumcorticosteroids
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2006-002107-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002107-13.